Sanofi Reports long-term follow-up Data for Filgotinib in Hepatitis C

Sanofi today announced long-term follow-up results for filgotinib in patients with hepatitis C. The study demonstrated that filgotinib demonstrates sustained efficacy compared to standard of care or placebo. These results provide important insights into the treatment of hepatitis C and support the continued development of filgotinib in this patient population. The data were presented at a major medical conference and will be submitted for publication in a peer-reviewed journal. Regulatory submissions are planned based on these results.